Industry: Healthcare Region: South Korea Transaction Price: USD 1 million Transaction Method: Equity Investment
Project introduction:
The company's product is a primary screening product, which takes urine as a sample and detects colon cancer, stomach cancer, lung cancer, liver cancer and pancreatic cancer in about 20 minutes.
The company's products are not only in-vitro diagnostic products for professional medical personnel, but also for quasi-professional medical personnel and non-professional medical personnel. Connected with computers and mobile phones, they can also be used for cancer examination in daily life such as medical institutions, families and offices.
In addition, urine can be collected in a non-invasive way, so it will not be accompanied by side effects, pain, etc., and can be checked at any time.
The company's in vitro diagnosis products can be used for cancer examination simply and quickly, so it can improve people's familiarity with cancer examination and early diagnosis rate, which will help eliminate people's fear of cancer and improve the survival rate of plague.
Cooperation mode:
Looking for importers, agents and partners in China.